Improved disease activity with fosdagrocorat (PF‐04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study

por Stock, Thomas, Fleishaker, Dona, Wang, Xin, Mukherjee, Arnab, Mebus, Charles
Publicado 2017

Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study

por Fleishaker, Dona L., Mukherjee, Arnab, Whaley, Fredrick S., Daniel, Shanthini, Zeiher, Bernhardt G.
Publicado 2016

In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF‐00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor

por Ripp, Sharon L., Mukherjee, Arnab, Eng, Heather, Stock, Thomas, Fleishaker, Dona, Checchio, Tina, Tammara, Brinda
Publicado 2017

Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial

por Østergaard, Mikkel, Wu, Joseph, Fallon, Lara, Sherlock, Sarah P., Wang, Cunshan, Fleishaker, Dona, Kanik, Keith S., Maksymowych, Walter P.
Publicado 2023

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies

por Orbai, Ana-Maria, Mease, Philip J., Helliwell, Philip S., FitzGerald, Oliver, Fleishaker, Dona L., Mundayat, Rajiv, Young, Pamela
Publicado 2022

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

por van der Heijde, Désirée, Deodhar, Atul, Wei, James C, Drescher, Edit, Fleishaker, Dona, Hendrikx, Thijs, Li, David, Menon, Sujatha, Kanik, Keith S
Publicado 2017

Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients

por Maksymowych, Walter P, van der Heijde, Désirée, Baraliakos, Xenofon, Deodhar, Atul, Sherlock, Sarah P, Li, David, Fleishaker, Dona, Hendrikx, Thijs, Kanik, Keith S
Publicado 2018

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib

por Dikranian, Ara, Gold, David, Bessette, Louis, Nash, Peter, Azevedo, Valderilio F., Wang, Lisy, Woolcott, John, Shapiro, Andrea B., Szumski, Annette, Fleishaker, Dona, Wollenhaupt, Jürgen
Publicado 2021

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis rece...

por Kristensen, Lars E., Strober, Bruce, Poddubnyy, Denis, Leung, Ying-Ying, Jo, Hyejin, Kwok, Kenneth, Vranic, Ivana, Fleishaker, Dona L., Fallon, Lara, Yndestad, Arne, Gladman, Dafna D.
Publicado 2023

Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, d...

por Navarro-Compán, Victoria, Wei, James Cheng-­Chung, Van den Bosch, Filip, Magrey, Marina, Wang, Lisy, Fleishaker, Dona, Cappelleri, Joseph C, Wang, Cunshan, Wu, Joseph, Dina, Oluwaseyi, Fallon, Lara, Strand, Vibeke
Publicado 2022

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled...

por Fleishaker, Dona L, Garcia Meijide, Juan A, Petrov, Andriy, Kohen, Michael David, Wang, Xin, Menon, Sujatha, Stock, Thomas C, Mebus, Charles A, Goodrich, James M, Mayer, Howard B, Zeiher, Bernhardt G
Publicado 2012

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

por Deodhar, Atul, Sliwinska-Stanczyk, Paula, Xu, Huji, Baraliakos, Xenofon, Gensler, Lianne S, Fleishaker, Dona, Wang, Lisy, Wu, Joseph, Menon, Sujatha, Wang, Cunshan, Dina, Oluwaseyi, Fallon, Lara, Kanik, Keith S, van der Heijde, Désirée
Publicado 2021

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

por Nash, Peter, Coates, Laura C., Kivitz, Alan J., Mease, Philip J., Gladman, Dafna D., Covarrubias-Cobos, José A., FitzGerald, Oliver, Fleishaker, Dona, Wang, Cunshan, Wu, Joseph, Hsu, Ming-Ann, Menon, Sujatha, Fallon, Lara, Romero, Ana Belén, Kanik, Keith S.
Publicado 2020